Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 41807 | 15.6167 |
09:34 ET | 6895 | 15.56 |
09:36 ET | 27419 | 15.4723 |
09:38 ET | 29142 | 15.44 |
09:39 ET | 14180 | 15.3801 |
09:41 ET | 8076 | 15.435 |
09:43 ET | 5308 | 15.56 |
09:45 ET | 958 | 15.55 |
09:48 ET | 7086 | 15.475 |
09:50 ET | 5101 | 15.475 |
09:52 ET | 4600 | 15.545 |
09:54 ET | 2925 | 15.51 |
09:56 ET | 25831 | 15.54 |
09:57 ET | 5307 | 15.5369 |
09:59 ET | 6426 | 15.5 |
10:01 ET | 7704 | 15.53 |
10:03 ET | 10667 | 15.6 |
10:06 ET | 11722 | 15.58 |
10:08 ET | 2080 | 15.55 |
10:10 ET | 6351 | 15.53 |
10:12 ET | 2656 | 15.55 |
10:14 ET | 1500 | 15.551 |
10:15 ET | 1312 | 15.545 |
10:17 ET | 1832 | 15.555 |
10:19 ET | 2328 | 15.605 |
10:21 ET | 4642 | 15.5541 |
10:24 ET | 2513 | 15.59 |
10:26 ET | 6013 | 15.61 |
10:28 ET | 3741 | 15.65 |
10:30 ET | 3842 | 15.635 |
10:32 ET | 8116 | 15.63 |
10:33 ET | 7835 | 15.6 |
10:35 ET | 2104 | 15.62 |
10:37 ET | 1100 | 15.63 |
10:39 ET | 695 | 15.62 |
10:42 ET | 3500 | 15.635 |
10:44 ET | 8153 | 15.68 |
10:46 ET | 4373 | 15.69 |
10:48 ET | 3816 | 15.68 |
10:50 ET | 2700 | 15.69 |
10:51 ET | 3098 | 15.645 |
10:53 ET | 1295 | 15.63 |
10:55 ET | 2071 | 15.63 |
10:57 ET | 2490 | 15.56 |
11:00 ET | 873 | 15.5779 |
11:02 ET | 2125 | 15.55 |
11:04 ET | 1400 | 15.565 |
11:06 ET | 3079 | 15.54 |
11:08 ET | 10000 | 15.55 |
11:09 ET | 3290 | 15.55 |
11:11 ET | 2821 | 15.5279 |
11:13 ET | 1500 | 15.565 |
11:15 ET | 5500 | 15.57 |
11:18 ET | 27193 | 15.59 |
11:20 ET | 3704 | 15.58 |
11:22 ET | 8972 | 15.53 |
11:24 ET | 4037 | 15.64 |
11:26 ET | 6525 | 15.67 |
11:27 ET | 9966 | 15.665 |
11:29 ET | 100 | 15.665 |
11:31 ET | 4342 | 15.69 |
11:33 ET | 1400 | 15.7 |
11:36 ET | 7299 | 15.72 |
11:38 ET | 2402 | 15.705 |
11:40 ET | 2010 | 15.695 |
11:42 ET | 2200 | 15.7 |
11:44 ET | 3477 | 15.7 |
11:45 ET | 24433 | 15.68 |
11:47 ET | 2435 | 15.73 |
11:49 ET | 4093 | 15.69 |
11:51 ET | 7878 | 15.69 |
11:54 ET | 1300 | 15.675 |
11:56 ET | 1000 | 15.68 |
11:58 ET | 1400 | 15.67 |
12:00 ET | 4914 | 15.61 |
12:02 ET | 13900 | 15.61 |
12:03 ET | 3269 | 15.59 |
12:05 ET | 1901 | 15.61 |
12:07 ET | 842 | 15.62 |
12:09 ET | 4248 | 15.61 |
12:12 ET | 1519 | 15.605 |
12:14 ET | 1007 | 15.61 |
12:16 ET | 1258 | 15.6 |
12:18 ET | 2245 | 15.6 |
12:20 ET | 12956 | 15.61 |
12:21 ET | 4670 | 15.6 |
12:23 ET | 2039 | 15.6 |
12:25 ET | 4103 | 15.605 |
12:27 ET | 2894 | 15.56 |
12:32 ET | 10451 | 15.575 |
12:34 ET | 1400 | 15.58 |
12:36 ET | 3547 | 15.545 |
12:38 ET | 2900 | 15.53 |
12:39 ET | 2200 | 15.5301 |
12:41 ET | 2113 | 15.54 |
12:43 ET | 3268 | 15.55 |
12:45 ET | 500 | 15.54 |
12:48 ET | 3180 | 15.535 |
12:50 ET | 3834 | 15.54 |
12:52 ET | 3091 | 15.53 |
12:54 ET | 4264 | 15.54 |
12:56 ET | 3888 | 15.58 |
12:57 ET | 800 | 15.59 |
12:59 ET | 3209 | 15.59 |
01:01 ET | 1300 | 15.59 |
01:03 ET | 2806 | 15.62 |
01:06 ET | 7783 | 15.61 |
01:08 ET | 2533 | 15.625 |
01:10 ET | 7043 | 15.625 |
01:12 ET | 8514 | 15.59 |
01:14 ET | 4753 | 15.585 |
01:15 ET | 600 | 15.59 |
01:17 ET | 1627 | 15.63 |
01:19 ET | 1200 | 15.64 |
01:21 ET | 983 | 15.65 |
01:24 ET | 3835 | 15.64 |
01:26 ET | 1697 | 15.63 |
01:28 ET | 1212 | 15.61 |
01:30 ET | 800 | 15.56 |
01:32 ET | 3376 | 15.53 |
01:33 ET | 1764 | 15.51 |
01:35 ET | 2256 | 15.52 |
01:37 ET | 1600 | 15.5312 |
01:39 ET | 500 | 15.538 |
01:42 ET | 1500 | 15.5405 |
01:44 ET | 12438 | 15.58 |
01:46 ET | 2300 | 15.57 |
01:48 ET | 3138 | 15.565 |
01:50 ET | 3773 | 15.56 |
01:51 ET | 2811 | 15.53 |
01:53 ET | 3136 | 15.53 |
01:55 ET | 1846 | 15.51 |
01:57 ET | 2000 | 15.51 |
02:00 ET | 2481 | 15.53 |
02:02 ET | 7760 | 15.49 |
02:04 ET | 3235 | 15.518 |
02:06 ET | 6072 | 15.485 |
02:08 ET | 4965 | 15.495 |
02:09 ET | 7436 | 15.53 |
02:11 ET | 1000 | 15.54 |
02:13 ET | 2700 | 15.555 |
02:15 ET | 5528 | 15.56 |
02:18 ET | 10632 | 15.61 |
02:20 ET | 10460 | 15.61 |
02:22 ET | 5978 | 15.6551 |
02:24 ET | 10452 | 15.67 |
02:26 ET | 4657 | 15.6898 |
02:27 ET | 2000 | 15.699 |
02:29 ET | 9783 | 15.73 |
02:31 ET | 16018 | 15.7 |
02:33 ET | 3644 | 15.705 |
02:36 ET | 5666 | 15.68 |
02:38 ET | 4112 | 15.66 |
02:40 ET | 2156 | 15.69 |
02:42 ET | 6509 | 15.67 |
02:44 ET | 2567 | 15.7 |
02:45 ET | 5548 | 15.7099 |
02:47 ET | 1000 | 15.7 |
02:49 ET | 1200 | 15.71 |
02:51 ET | 9736 | 15.68 |
02:54 ET | 2528 | 15.685 |
02:56 ET | 3326 | 15.69 |
02:58 ET | 10100 | 15.705 |
03:00 ET | 33011 | 15.72 |
03:02 ET | 12841 | 15.725 |
03:03 ET | 4300 | 15.72 |
03:05 ET | 1132 | 15.75 |
03:07 ET | 6922 | 15.735 |
03:09 ET | 9581 | 15.695 |
03:12 ET | 4846 | 15.72 |
03:14 ET | 3600 | 15.735 |
03:16 ET | 1200 | 15.73 |
03:18 ET | 11948 | 15.75 |
03:20 ET | 11462 | 15.7681 |
03:21 ET | 8750 | 15.775 |
03:23 ET | 6363 | 15.78 |
03:25 ET | 31195 | 15.85 |
03:27 ET | 11153 | 15.85 |
03:30 ET | 19351 | 15.91 |
03:32 ET | 11893 | 15.89 |
03:34 ET | 21497 | 15.89 |
03:36 ET | 4604 | 15.89 |
03:38 ET | 15181 | 15.885 |
03:39 ET | 6207 | 15.9 |
03:41 ET | 11005 | 15.895 |
03:43 ET | 15428 | 15.86 |
03:45 ET | 4761 | 15.875 |
03:48 ET | 9788 | 15.89 |
03:50 ET | 12555 | 15.915 |
03:52 ET | 21988 | 15.93 |
03:54 ET | 29066 | 15.905 |
03:56 ET | 40459 | 15.89 |
03:57 ET | 38267 | 15.875 |
03:59 ET | 99626 | 15.85 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 2.5B | 71.9x | --- |
Twist Bioscience Corp | 2.7B | -15.1x | --- |
ADMA Biologics Inc | 2.3B | -513.2x | --- |
Vericel Corp | 2.2B | 4,642.3x | --- |
Maravai LifeSciences Holdings Inc | 2.2B | -8.7x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -5.6x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 71.9x |
Price/Sales (TTM) | 8.8 |
Price/Cash Flow (TTM) | 61.8x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.